to CarringtonLangford,
mate, I reckon it needs to be on this thread:
"The more time I have spent researching MSB and its stem cell product pipeline the more impressed I am as I feel the company is on the cutting edge of 21st century biological technology that will totally revolutionise the treatment of a host of diseases and ailments. MSB is specifically targeting cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions.
I am absolutely astounded with how advanced the company is with their portfolio of cell-based products which include five programs in active Phase 3 clinical studies or Phase 3-ready, and four programs in Phase 2. MSB appears to be one of the companies at the vanguard of this blockbuster technology, which only a score ago was the stuff of dreams and science fiction. I have had a good look at the qualifications and experience of the board of directors and management team and have to say I am very impressed. I will be buying in."
I'm calling it..., page-61
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
-0.008(0.54%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.42 | $1.38 | $3.330M | 2.390M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 21850 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 40145 | 30 |
View Market Depth
| Last trade - 15.13pm 10/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |